Herlapsa (lapatinib 250 mg) is a generic kinase inhibitor that is used to treat breast cancer. Specifically, it is prescribed for the following conditions:
Advanced or metastatic breast cancer patients who have tumors that overexpress the human epidermal growth factor receptor 2 (HER2) and who have previously been treated with an anthracycline, a taxane, and trastuzumab. These patients can be treated with capecitabine. It is important to note that treatment with lapatinib in combination with capecitabine should only be started if the patient's disease has progressed while on trastuzumab.
Postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor and who require hormonal therapy can be treated with Letrozole. It should be noted that the effectiveness of lapatinib in combination with an aromatase inhibitor has not been compared to a chemotherapy regimen that contains trastuzumab for the treatment of metastatic breast cancer.
To treat advanced or metastatic breast cancer, the recommended daily dose of Lapatinib is 1,250 mg (equivalent to 5 tablets) taken orally once a day for 21 days, in combination with capecitabine 2,000 mg/m2/day taken orally twice a day for 14 days, in a repeating 21-day cycle.
For hormone receptor-positive, HER2-positive metastatic breast cancer, the recommended daily dose of Lapatinib is 1,500 mg (equivalent to 6 tablets) taken orally once a day continuously, in combination with letrozole at a dose of 2.5 mg taken orally once a day. It is important to take Lapatinib as a single daily dose, at least one hour before or after a meal, and to take capecitabine with food or within 30 minutes after eating.
The dose of Lapatinib may need to be adjusted if the patient experiences cardiac or other toxicities, severe hepatic impairment, diarrhea, or if they are taking medications that interact with CYP3A4.
Lapatinib 250 mg price :
In India, Lapatinib generic or Lapatinib 250mg is priced at only 10% of the cost in other countries.
Hertab 250 mg Side Effects：
Severe side effects may result from taking Lapatinib, including heart problems such as an irregular heartbeat and reduced heart function, which can cause dizziness, shortness of breath, and fatigue. Your healthcare provider should monitor your heart function both before and during treatment.
Liver problems may also arise, with symptoms like abdominal pain, itching, and yellowing of the skin or eyes. Regular liver function tests should be done before and during treatment.
Diarrhea is a common side effect, which may sometimes be severe enough to cause dehydration. If you experience severe diarrhea or changes in bowel habits, notify your healthcare provider right away.
In addition, Lapatinib can cause lung problems, severe skin reactions, and red and painful hands and feet. If you experience any of these symptoms, discontinue taking Lapatinib immediately and contact your healthcare provider.
When taken in combination with capecitabine or letrozole, common side effects of Lapatinib include diarrhea, nausea, vomiting, rash, and fatigue. If you experience any side effects that persist or are bothersome, inform your healthcare provider.
It is important to remember that this is not an exhaustive list of possible side effects, so consult your healthcare provider for more information. To learn more about prescribing Lapatinib, refer to the FDA prescribing information.
|Don't take the drug without consulting a qualified doctor or physician
|Follow the doctor's advice
|Delivery & Returns